Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Sep;292(3):536-539.
doi: 10.1111/joim.13490. Epub 2022 Apr 10.

Soluble CD163 and incident cardiovascular events in patients with systemic lupus erythematosus: An observational cohort study

Clémence David  1 , Nathalie Costedoat-Chalumeau  2 , Drifa Belhadi  3 , Cedric Laouénan  3 , Anne Boutten  4 , Julie Chezel  1 , Diane Rouzaud  1 , Monique Dehoux  4 , Véronique Le Guern  2 , Alexis Mathian  5 , Sébastien de Almeida Chaves  6 , Pierre Duhaut  7 , Olivier Fain  8 , Lionel Galicier  9 , Pascale Ghillani-Dalbin  10 , Jean Emmanuel Kahn  11 , Nathalie Morel  2 , Laurent Perard  12 , Micheline Pha  5 , Francoise Sarrot-Reynauld  13 , Olivier Aumaitre  14 , François Chasset  15 , Nicolas Limal  16 , Helene Desmurs-Clavel  17 , Felix Ackermann  18 , Zahir Amoura  5 , Thomas Papo  1 , Karim Sacre  1
Affiliations
Observational Study

Soluble CD163 and incident cardiovascular events in patients with systemic lupus erythematosus: An observational cohort study

Clémence David et al. J Intern Med. 2022 Sep.
No abstract available

Keywords: CD163; biomarkers; cardiovascular diseases; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves reflecting cumulative proportion of systemic lupus erythematosus (SLE) patients free of CVE according to sCD163 level. Analysis was performed on 438 patients. Abbreviation: CVE, cardiovascular event.
See this image and copyright information in PMC

References

    1. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331–7. - PubMed
    1. Mejia‐Vilet JM, Zhang XL, Cruz C, Cano‐Verduzco ML, Shapiro JP, Nagaraja HN, et al. Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis. J Am Soc Nephrol. 2020;31:1335–47. - PMC - PubMed
    1. David C, Divard G, Abbas R, Escoubet B, Chezel J, Chauveheid MP, et al. Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease. Scand J Rheumatol. 2020;49:33–7. - PubMed
    1. Costedoat‐Chalumeau N, Galicier L, Aumaître O, Francès C, Le Guern V, Lioté F, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis. 2013;72:1786–92. - PubMed
    1. Chezel J, Costedoat‐Chalumeau N, Laouénan C, Rouzand D, Chenevier‐Gobeaux C, Le Guern V, et al. Highly sensitive serum cardiac troponin T and cardiovascular events in patients with systemic lupus erythematosus (TROPOPLUS study). Rheumatology (Oxford). 2021;60:1210–1215. - PubMed

MeSH terms